Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

As myopia becomes a worldwide epidemic, the upcoming Paris workshop on September 8, 2025, will convene global leaders to discuss strategies, research priorities, and new treatment pathways.

Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting

AI enhances home OCT imaging to track wet AMD disease activity, enabling personalized patient management and improved treatment response monitoring.

Study finds value in home OCT monitoring

Michael X. Repka, MD, MBA, is the current president of the American Academy of Ophthalmology.

Videos

Ahead of the September 8 meeting in Paris, the program co-chair of the event and current president of the American Academy of Ophthalmology discusses how the workshop aims to shape consensus on guidelines, research priorities, and emerging therapies in myopia control.

CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions

A novel use of minor salivary glands offers lasting relief and visual improvement.

Surgical innovation in dry eye disease: Salivary gland transplant

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

New York-The 1-year follow-up of the Hydroview IOL (Bausch & Lomb) indicates that the lens is safe and provides excellent postoperative visual outcomes, a low incidence of Nd:YAG capsulotomy, and no cases of decentration, according to Douglas Grayson, MD, FACS.

Hydrophilic IOL yields low incidence of Nd:YAG capsulotomy

Hydrophilic IOL yields low incidence of Nd:YAG capsulotomy

Newsletter